Clinical trial
Lab Study of MQX-503 in Treatment of Raynaud's
NCT00253331 · MediQuest Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00253331 |
|---|---|
| Title | Lab Study of MQX-503 in Treatment of Raynaud's |
| Official title | Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon |
| Lead sponsor | MediQuest Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease |
| Intervention type | Drug |
| Interventions | topical organogel with nitroglycerin |
| Enrollment | 36 |
| Start date | Nov 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Nov 15, 2005 |
| Last update posted | May 30, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: